CD40LG/CD28-Mediated Rho GTPase Signaling Drives Survival and Chemoresistance in Non-ETP T-ALL

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• T-cell acute lymphoblastic leukemia (T-ALL), particularly the non-early T-cell precursor (non-ETP) subtype, presents aggressive clinical behavior and poor outcomes.
• Despite advances in understanding T-ALL genetics, the molecular drivers of non-ETP T-ALL pathogenesis and therapeutic resistance remain incompletely elucidated.

Purpose of the Study:

• To investigate the molecular mechanisms driving non-ETP T-ALL progression and therapeutic resistance.
• To identify novel therapeutic targets and strategies for non-ETP T-ALL.

Main Methods:

• Functional assays using non-ETP T-ALL cell lines and xenograft models.
• Transcriptomic profiling via RNA sequencing (RNA-seq) and bioinformatic analysis.
• Mining of clinical patient datasets for survival outcome analysis.

Main Results:

• CD40 ligand (CD40LG) and CD28 activation enhance non-ETP T-ALL cell proliferation and migration, with CD40LG upregulating CXCR4 for bone marrow homing.
• Rho GTPase signaling (RhoA/Rac1/Rac2) acts as a downstream effector of CD40LG/CD28, mediating resistance to PI3K inhibitors.
• Pharmacological inhibition of RhoA or Rac1 demonstrated significant cytotoxicity and sensitized resistant cells to PI3K inhibitors in vitro and in vivo.
• Elevated expression of CD40LG, CD28, RHOA, or RAC2 correlated with poor prognosis in non-ETP T-ALL patients.

Conclusions:

• A novel CD40LG/CD28-Rho GTPase signaling axis is identified as a key driver in non-ETP T-ALL pathogenesis.
• This axis represents a potential therapeutic vulnerability, offering a target for precision intervention.
• Targeting the CD40LG/CD28-Rho GTPase pathway presents a promising strategy to overcome therapeutic resistance in non-ETP T-ALL.